Fludarabine
Rhabdoid Tumor
St. Jude Children's Research HospitalSmall moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
33 Active assets in the Rhabdoid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tazemetostat Epizyme, Inc. | Phase 2 | BB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | B |
Hycamtin Pfizer | Phase 2 | B |
Olaparib National Cancer Institute (NCI) | Phase 2 | B |
PI3K/MTOR INHIBITOR LY3023414 National Cancer Institute (NCI) | Phase 2 | B |
View all 44 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →